These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 12041693)
21. Effect of inhibition of synthesis of inducible nitric oxide synthase-derived nitric oxide by aminoguanidine on the in vitro maturation of oocyte-cumulus complexes of cattle. Matta SG; Caldas-Bussiere MC; Viana KS; Faes MR; Paes de Carvalho CS; Dias BL; Quirino CR Anim Reprod Sci; 2009 Apr; 111(2-4):189-201. PubMed ID: 18439771 [TBL] [Abstract][Full Text] [Related]
22. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752 [TBL] [Abstract][Full Text] [Related]
23. Tissue plasminogen activator activity in human aqueous humor. Smalley DM; Fitzgerald JE; Taylor DM; Cone RE; O'Rourke J Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):48-53. PubMed ID: 8300363 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage. Zhang X; Chaudhry A; Chintala SK Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409 [TBL] [Abstract][Full Text] [Related]
25. Evidence for an active fibrinolytic system in normal human bone marrow. McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456 [TBL] [Abstract][Full Text] [Related]
26. The promotory effect of growth hormone on the developmental competence of in vitro matured bovine oocytes is due to improved cytoplasmic maturation. Izadyar F; Hage WJ; Colenbrander B; Bevers MM Mol Reprod Dev; 1998 Apr; 49(4):444-53. PubMed ID: 9508096 [TBL] [Abstract][Full Text] [Related]
27. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator. Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141 [TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Jänicke F; Schmitt M; Graeff H Semin Thromb Hemost; 1991 Jul; 17(3):303-12. PubMed ID: 1796300 [No Abstract] [Full Text] [Related]
29. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study. De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228 [TBL] [Abstract][Full Text] [Related]
30. Release of tissue-type plasminogen activator by activated rat eggs and its possible role in the zona reaction. Zhang X; Rutledge J; Khamsi F; Armstrong DT Mol Reprod Dev; 1992 May; 32(1):28-32. PubMed ID: 1515147 [TBL] [Abstract][Full Text] [Related]
31. Oocytes use the plasminogen-plasmin system to remove supernumerary spermatozoa. Coy P; Jiménez-Movilla M; García-Vázquez FA; Mondéjar I; Grullón L; Romar R Hum Reprod; 2012 Jul; 27(7):1985-93. PubMed ID: 22556378 [TBL] [Abstract][Full Text] [Related]
32. Morphology and subsequent development in culture of bovine oocytes matured in vitro under various conditions of fertilization. Long CR; Damiani P; Pinto-Correia C; MacLean RA; Duby RT; Robl JM J Reprod Fertil; 1994 Nov; 102(2):361-9. PubMed ID: 7861389 [TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of plasminogen activators in human gingival crevicular fluid. Brown JM; Watanabe K; Cohen RL; Chambers DA Arch Oral Biol; 1995 Sep; 40(9):839-45. PubMed ID: 8651888 [TBL] [Abstract][Full Text] [Related]
34. [Tissue plasminogen activator and plasminogen activator inhibitor in aqueous humor]. Giedrojć J; Stankiewicz A; Walkowiak M; Galar M; Bielawiec M Klin Oczna; 1996; 98(4):283-5. PubMed ID: 9463119 [TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays. Camiolo SM; Greco WR Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257 [TBL] [Abstract][Full Text] [Related]
37. Distribution of plasminogen activator in different fractions of bovine milk. White JH; Zavizion B; O'Hare K; Gilmore J; Guo MR; Kindstedt P; Politis I J Dairy Res; 1995 Feb; 62(1):115-22. PubMed ID: 7738239 [TBL] [Abstract][Full Text] [Related]
38. Ultrastructural modifications in bovine oocytes maintained in meiotic arrest in vitro using roscovitine or butyrolactone. Lonergan P; Faerge I; Hyttel PM; Boland M; Fair T Mol Reprod Dev; 2003 Mar; 64(3):369-78. PubMed ID: 12548669 [TBL] [Abstract][Full Text] [Related]
39. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Thorsen S; Philips M; Selmer J; Lecander I; Astedt B Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015 [TBL] [Abstract][Full Text] [Related]
40. Plasminogen activator activity in the bovine oocyte-cumulus complex and early embryo. Yamada M; Horiuchi T; Oribe T; Yamamoto S; Matsushita H; Gentry PA J Vet Med Sci; 1996 Apr; 58(4):317-22. PubMed ID: 8741263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]